tetano
Editor, Senior Moderator
Diabetes Res Clin Pract. 2020 Apr 23:108162. doi: 10.1016/j.diabres.2020.108162. [Epub ahead of print]
SARS-CoV-2 and DPP4 inhibition: is it time to pray for Janus Bifrons?
Pitocco D[SUP]1[/SUP], Tartaglione L[SUP]2[/SUP], Viti L[SUP]2[/SUP], Di Leo M[SUP]2[/SUP], Pontecorvi A[SUP]3[/SUP], Caputo S[SUP]2[/SUP].
Author information
Abstract
Diabetes could be a risk factor for severity and mortality in patients with coronavirus disease 2019 Covid-19. It has been hypothesized that DPP4 inhibition, a therapy currently available for type 2 diabetes, might represent a target for decreasing the risk of the acute respiratory complications of the COVID-19 infection but 1) lack of demonstration of SARS-CoV2 binding to DPP4 2) possible protective role of sDPP4 in Middle East respiratory Syndrome (MERS-CoV 3) demonstrated inhibition and downregulation of DPP4 by HIV1 and MERS-CoV and 4) not exclusive role of the receptor binding in tropism of the Coronavirus family, support that DPP4 inhibition at present doesn't represent a plausible approach to mitigate Covid-19.
Copyright ? 2020 Elsevier B.V. All rights reserved.
KEYWORDS:
ACE 2; COVID 19; DPP4; Diabetes
PMID:32335097DOI:10.1016/j.diabres.2020.108162
SARS-CoV-2 and DPP4 inhibition: is it time to pray for Janus Bifrons?
Pitocco D[SUP]1[/SUP], Tartaglione L[SUP]2[/SUP], Viti L[SUP]2[/SUP], Di Leo M[SUP]2[/SUP], Pontecorvi A[SUP]3[/SUP], Caputo S[SUP]2[/SUP].
Author information
Abstract
Diabetes could be a risk factor for severity and mortality in patients with coronavirus disease 2019 Covid-19. It has been hypothesized that DPP4 inhibition, a therapy currently available for type 2 diabetes, might represent a target for decreasing the risk of the acute respiratory complications of the COVID-19 infection but 1) lack of demonstration of SARS-CoV2 binding to DPP4 2) possible protective role of sDPP4 in Middle East respiratory Syndrome (MERS-CoV 3) demonstrated inhibition and downregulation of DPP4 by HIV1 and MERS-CoV and 4) not exclusive role of the receptor binding in tropism of the Coronavirus family, support that DPP4 inhibition at present doesn't represent a plausible approach to mitigate Covid-19.
Copyright ? 2020 Elsevier B.V. All rights reserved.
KEYWORDS:
ACE 2; COVID 19; DPP4; Diabetes
PMID:32335097DOI:10.1016/j.diabres.2020.108162